Similarly, Freund-Levi et al. (2008) found that n-3 PUFA treatment with 1.7 g DHA and 0.6 g daily supplementation led to significant improvements in neuropsychiatric symptoms, including potentially positive effects on depressive symptoms in non-APOE omega4 carriers and agitation symptoms in APOE omega4 carriers among patients with mild to moderate Alzheimer’s disease [111]. The gene discussed is APOE; the disease is early-onset autosomal dominant Alzheimer disease.